Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

10322	Companies
213990	Keywords
143687	Articles
113275	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 04/10/2026 at 02:20, 20 days 3 hours ago

Jaguar Health Schedules Investor Webcast on Q4 2025 Financials

Financial Updates Forward-looking Statements Investor Webcast Jaguar Health Gastrointestinal Treatments
PRESS RELEASE

published on 04/10/2026 at 02:15, 20 days 3 hours ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Jaguar Health, Inc. announces participation details for upcoming webcast on April 10, 2026. Learn about their novel prescription drugs derived from plants for GI diseases

Forward-looking Statements Webcast Jaguar Health GI Diseases Prescription Drugs
BRIEF

published on 04/08/2026 at 14:35, 21 days 15 hours ago

Jaguar Health Completes Crofelemer Trial for CID in Dogs

Crofelemer FDA Approval Jaguar Health Dog Chemotherapy Diarrhea Treatment
PRESS RELEASE

published on 04/08/2026 at 14:30, 21 days 15 hours ago

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. completes study on crofelemer for cancer therapy-induced diarrhea in dogs. Results expected to complement positive outcomes. Company plans to file effectiveness study by Q2 2026

Crofelemer Jaguar Health Cancer Therapy Diarrhea Dogs
BRIEF

published on 04/07/2026 at 14:35, 22 days 15 hours ago

Jaguar Health Reports Mixed Financial Results for 2025

Jaguar Health Financial Results 2025 Crofelemer Drugs Nasdaq Appeal Future Pak Agreement
PRESS RELEASE

published on 04/07/2026 at 14:30, 22 days 15 hours ago

Jaguar Health Reports 2025 Financials
Jaguar Health, Inc. reports a 5% increase in net revenue in Q4 2025 compared to Q3 2025. Company receives $16M upfront payment from Future Pak for license agreement. Financial results include revenue breakdown and operational expenses

Financial Results Jaguar Health License Agreement Q4 2025 Net Revenue Increase
BRIEF

published on 04/02/2026 at 15:05, 27 days 15 hours ago

Jaguar Health Co-Sponsors Pediatric Gastroenterology Conference

Pediatric Gastroenterology Clinical Study Results Crofelemer Development ELITE PED-GI Congress Intestinal Failure
PRESS RELEASE

published on 04/02/2026 at 15:00, 27 days 15 hours ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar Health's crofelemer program targeting intestinal failure shows promising results with reductions in parenteral support for pediatric patients. Company sponsors ELITE PED-GI Congress in Abu Dhabi

Jaguar Health ELITE PED-GI Congress Intestinal Failure Parenteral Support Reduction Crofelemer Program
BRIEF

published on 03/24/2026 at 14:44, 1 month 5 days ago

Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

BUY Rating Jaguar Health Healthcare Innovation Market Potential First Berlin
PRESS RELEASE

published on 03/24/2026 at 14:39, 1 month 5 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research initiates coverage on Northwest Biotherapeutics Inc., providing insights into the company's late-stage oncology developments including the promising DCVax-L immunotherapy for glioblastoma

First Berlin Equity Research Northwest Biotherapeutics Inc. DCVax-L Immunotherapy Late-stage Oncology Developments USD 1.00 Price Target

Accesswire

Published on 04/30/2026 at 01:35, 4 hours 36 minutes ago

Kalo Gold Provides Update on High-Resolution Airborne Magnetic Survey at Vatu Aurum Project, Fiji
Published on 04/30/2026 at 01:15, 4 hours 56 minutes ago

Credissential Announces Shares Consolidation
Published on 04/30/2026 at 00:49, 5 hours 22 minutes ago

Fourth Quarter and Year-End 2025 Results
Published on 04/30/2026 at 00:00, 6 hours 11 minutes ago

Redwood AI CEO Highlights Role of its AI Technology Within Aidos-Led B.C. Government's Track and Trace Pilot Program on Conversations That Matter TV Series, Featured in the Vancouver Sun
Published on 04/29/2026 at 23:58, 6 hours 13 minutes ago

Roxmore Announces Filing of Meeting Materials for Upcoming Shareholders Meeting

View all ACCESSWIRE

EQS Group

Published on 04/30/2026 at 03:05, 3 hours 6 minutes ago

Cohen & Steers Renames UCITS Preferred Securities Strategies as Hybrid Credit Strategies
Published on 04/29/2026 at 23:42, 6 hours 29 minutes ago

H2APEX publishes figures for the 2025 financial year and provides positive outlook
Published on 04/29/2026 at 23:01, 7 hours 10 minutes ago

Sirma Delivers 31% Revenue Growth in 2025 and Advances AI Platform Strategy
Published on 04/29/2026 at 22:15, 7 hours 56 minutes ago

Amrize Grows Revenue 4.7% in First Quarter and Reaffirms 2026 Guidance
Published on 04/29/2026 at 22:05, 8 hours 6 minutes ago

Evotec Announces New Nomination to Board of Directors

Les Echos

Published on 04/29/2026 at 23:00, 7 hours 11 minutes ago

INFORMATION ON ANNUAL FINANCIAL STATEMENTS
Published on 04/29/2026 at 18:31, 11 hours 40 minutes ago

FIRST QUARTER 2026 TURNOVER
Published on 04/29/2026 at 18:15, 11 hours 56 minutes ago

GUILLEMOT CORPORATION | AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE 2025 ANNUAL FINANCIAL REPORT
Published on 04/29/2026 at 18:10, 12 hours 1 minute ago

Amemdment of the resolution n8 submitted to the AGM of 30 April 2026
Published on 04/29/2026 at 18:00, 12 hours 11 minutes ago

Availability of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE